¾«¶«Ó°Òµ

¾«¶«Ó°Òµ. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical manufacturing subsidiary “¾«¶«Ó°ÒµManufacturing Ltd.” (EML) in Hatfield, United Kingdom. EML is owned by the Company's European regional headquarters, ¾«¶«Ó°ÒµEurope Limited (Headquarters: London, President: Yutaka Tsuchiya).

EML, which is the Company's first manufacturing facility in Europe, will function as the core base of quality assurance and supply chain management for the Eisai's European operations. Establishment of our own manufacturing base in Europe aims to enhance Eisai's global supply chain, ensuring the Company's commitment to a stable supply of safe and high-quality products across Europe. In addition, EML will be recruiting manufacturing/quality assurance experts by the targeted operation launch in FY 2008.

¾«¶«Ó°Òµhas been rapidly expanding its European operations with the planned construction of the European Knowledge Center. Located in the pharmaceutical cluster to the north of London Hatfield, the Center will consolidate Eisai's all key value chain components in the entire region, including headquarters, discovery & clinical research, production, and marketing. Introduction of a new manufacturing subsidiary in Hatfield will lead to further progress in the Eisai's knowledge creation in manufacturing.

¾«¶«Ó°Òµis committed to satisfying the various medical needs and increasing the benefit to the patients and their families in Europe, through the stable supply of our high-quality products and information dissemination activities.